Cisapride for Gastroesophageal Reflux Disease: A Placebo‐Controlled, Double‐Blind Study

The American Journal of Gastroenterology

Volumn 90, Issue 3, 1995, Pages 423-430

  Richter, Joel E ^a,b   Long, James F ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; PLACEBO;

ACID SECRETION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; STOMACH ACID;

ALUMINUM HYDROXIDE; ANTACIDS; ANTI-ULCER AGENTS; CISAPRIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MAGNESIUM HYDROXIDE; MALE; MIDDLE AGED; PIPERIDINES; TIME FACTORS;

EID: 0028952615     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1995.tb08239.x     Document Type: Article

References (34)

1. Review article: Promotility drugs in the treatment of gaslrooesophageal reflux disease
2. Effect of cisapride on delayed gastric emptying in gastro‐oesophageal reflux disease
3. Stimulation of the incompetent lower esophageal sphincter. A possible advance in therapy of heart‐burn
4. Effect of bethanechol on gaslroesophageal reflux
5. Comparative effects of metoclopramide: and bethanechil on lower esophageal sphincter pressure in reflux patients
6. The effect of oral and intravenous meioclopramide on human lower esophageal sphincter pressure
7. Reflux esophagitis: Effect of oral bethanechol on symptoms and endnscnpic findings
8. Double‐blind controlled trail of bethanechol and antacid in the treatment of erosive esophagitis
9. Cimetidine, metoclopramide or placebo in the treatment of symptomatic gastroesophageal reflux
10. Prokinetic agents: A key in the future of gastroenterology
11. Metocloprarnide: Pharmacology clinical applications
12. Pathuphysiological rationale for the treatment of gastro‐oesophageal reflux disease with cisapride
13. Motor stimulating properties of cisapride on isolated gastrointestinal preparations in the guinea pig
14. Effect of cisapride. a new prokinctic agent, on esophageal motor function
15. Cisapride in gaslrooesophageal reflux disease: Effects on oesophageal motility and intraoesophageal pH
16. Assessment by prolonged ambulatory manometry of the effect of oral cisapride on proximal small bowel inter‐digestive motility
17. Effect of cisapride on relapse of esphagitis
18. Healing of grade‐II and III oesophagitis through motility stimulation with cisapride
19. Therapeutic effect of two dosages of cisapride in controlling chronic reflux symptoms in esophagitis patients‐ Curr
20. Dose‐response study with cisapride in gastroesophagea reflux disease
21. Cisapride versus placebo in refiux esophagitis. A multicenter double blind trial
22. Oral cisapride in OERD: A double‐blind placebo‐controlled multicentcr trial
23. Cisapride in the treatment of GERD: A double‐blind, placebo‐controled multicenter dose‐response trial
24. Management of gastrooe‐sophageal reflux disease
25. Drug therapy of reflux oesophagilis: An update
26. Reflux esophagitis
27. Clinical and economic factors in the selection of drugs for gaslroesophageal reflux disease
28. Double‐blind comparison of csapride and cimclidine in treatment of reflux esophagitis
29. Cisapride versus ranitidine in the treatment of rutlux esophagitis
30. Introduction to pathophysiology of gastroesophageal reflux
31. Esophageal acid sensitivity in Barrett's esophagus
32. Epidemiology of gastro‐esophagcal reflux disease
33. Treatment of reflux symptoms in esophagitis patients: Comparison trial of cisapride and metodopramide
34. The ACG Committee on FDA‐related Matters. Cisapride. A new class of prokinctic agent